<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02084849</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00041117</org_study_id>
    <secondary_id>0247-1998</secondary_id>
    <nct_id>NCT02084849</nct_id>
  </id_info>
  <brief_title>ADPKD Cohort Study</brief_title>
  <official_title>The Autosomal Dominant Polycystic Kidney Disease (ADPKD) Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PKD Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if radiology tests of the kidneys as opposed to&#xD;
      glomerular filtration (GFR) tests (GFR test - a lab test that measures kidney function)&#xD;
      follow progression of polycystic kidney disease (PKD) the best. PKD patients at risk for&#xD;
      progression to renal failure (dialysis or transplantation) have been identified and include&#xD;
      those who have been diagnosed with high blood pressure early, the presence of the PKD1 gene&#xD;
      (the inherited abnormality responsible for the majority of PKD), men as opposed to women,&#xD;
      those with episodes of visible blood or increased protein in their urine, and women who have&#xD;
      experience more than three pregnancies. Individuals who are diagnosed with PKD in the first&#xD;
      year of life or in utero (before birth) are also at high risk for progression to renal&#xD;
      failure.&#xD;
&#xD;
      This study will also facilitate understanding of human diseases at the cellular and molecular&#xD;
      level. We will be identifying genetic factors that may influence the severity of polycystic&#xD;
      kidney disease (PKD). You are being asked to provide a sample of blood for the purpose of DNA&#xD;
      or other biochemical analyses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 1998</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>84 Months</target_duration>
  <primary_outcome>
    <measure>Change in GFR as compared to change in renal volume over time</measure>
    <time_frame>Three years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in the ability to determine change in renal volume over time between MRI and ultrasound</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">624</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Group 1 will consist of 300 ADPKD individuals who are early in the course of their disease and demonstrate risk factors for progression to ESRD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Group 2 will consist of ADPKD subjects who have progressed to a more advanced stage of their renal disease. There is no limit with regard to the number of subjects to be recruited into this group.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, urine, tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        ADPKD individuals at risk for progression to End Stage Renal Disease (ESRD)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group 1&#xD;
&#xD;
          -  Hypertension diagnosed early in the course of the disease (less than 25 years for men;&#xD;
             less than 30 years for women)&#xD;
&#xD;
          -  ADPKD diagnosed in utero or in the first year of life&#xD;
&#xD;
          -  The presence of proteinuria (between 180 mg and 1 gm/day) without evidence of a second&#xD;
             renal disorder&#xD;
&#xD;
          -  A history of more than 3 pregnancies and hypertension&#xD;
&#xD;
          -  A history of gross hematuria&#xD;
&#xD;
          -  A serum creatinine concentration less than 1.4 mg/dl&#xD;
&#xD;
          -  ADPKD diagnosed in childhood with more than 10 cysts&#xD;
&#xD;
        Group 2&#xD;
&#xD;
          -  Serum creatinine concentration &gt;1.4 and&#xD;
&#xD;
          -  Renal length greater than 15 cm and&#xD;
&#xD;
          -  Age less than 60 years of age&#xD;
&#xD;
          -  Severe pain or discomfort as assessed by the primary care physician related to ADPKD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects, who in the assessment of the principal investigator cannot provide reliable&#xD;
             follow-up&#xD;
&#xD;
          -  Subjects who cannot be exposed to iothalamate&#xD;
&#xD;
          -  Subjects who cannot undergo MRI due to the presence of a pacemaker or surgical clip in&#xD;
             the abdomen&#xD;
&#xD;
          -  Subjects who are not anticipated to survive during the duration of the study (e.g.&#xD;
             underlying malignancy)&#xD;
&#xD;
          -  Subjects who cannot provide informed consent&#xD;
&#xD;
          -  Women who are pregnant or who have undergone a pregnancy in the last 6 months or who&#xD;
             are presently breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arlene Chapman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>March 10, 2014</study_first_submitted>
  <study_first_submitted_qc>March 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2014</study_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Arlene Chapman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

